| 1 |
Sripongpun P, Kaewdech A, Udompap P, et al. Characteristics and long-term mortality of individuals with MASLD, MetALD, and ALD, and the utility of SAFE score[J]. JHEP Rep, 2024, 6(10): 101127.
|
| 2 |
Ferraioli G, Barr RG, Berzigotti A, et al. WFUMB Guidelines/Guidance on liver multiparametric ultrasound. part 2: guidance on liver fat quantification[J]. Ultrasound Med Biol, 2024, 50(8): 1088-1098.
|
| 3 |
Paik JM, Hobbs K, Gupta A, et al. Prevalence of MASLD, Met-ALD, and ALD and associated fibrosis among US adults: insights from NHANES 2017 to 2023[J]. J Clin Gastroenterol, 2025 May 28. doi: 10.1097/MCG.0000000000002202. Epub ahead of print.
|
| 4 |
Sheka AC, Adeyi O, Thompson J, et al. Nonalcoholic steatohepatitis: A review[J]. JAMA, 2020, 323(12): 1175-1183.
|
| 5 |
Yip TC, Vilar-Gomez E, Petta S, et al. Geographical similarity and differences in the burden and genetic predisposition of NAFLD[J]. Hepatology, 2023, 77(4): 1404-1427.
|
| 6 |
Sandireddy R, Sakthivel S, Gupta P, et al. Systemic impacts of metabolic dysfunction-associated steatotic liver disease (MASLD) and metabolic dysfunction-associated steatohepatitis (MASH) on heart, muscle, and kidney related diseases[J]. Front Cell Dev Biol, 2024, 12: 1433857.
|
| 7 |
Bilson J, Mantovani A, Byrne CD, et al. Steatotic liver disease, MASLD and risk of chronic kidney disease[J]. Diabetes Metab, 2024, 50(1): 101506.
|
| 8 |
Qu Y, Song YY, Chen CW, et al. Diagnostic performance of fibrotouch ultrasound attenuation parameter and liver stiffness measurement in assessing hepatic steatosis and fibrosis in patients with nonalcoholic fatty liver disease[J]. Clin Transl Gastroenterol, 2021, 12(4): e00323.
|
| 9 |
Nishida N. Advancements in artificial intelligence-enhanced imaging diagnostics for the management of liver disease-applications and challenges in personalized care[J]. Bioengineering (Basel), 2024, 11(12): 1243.
|
| 10 |
Malik S, Das R, Thongtan T, et al. AI in hepatology: revolutionizing the diagnosis and management of liver disease[J]. J Clin Med, 2024, 13(24): 7833.
|
| 11 |
中华医学会肝脏病学分会脂肪肝和酒精性肝病学组. 非酒精性脂肪性肝病诊疗指南[J]. 中华肝脏病杂志, 2006, 14(3): 161-163.
|
| 12 |
Liu Z, Mao H, Wu CY, et al. A ConvNet for the 2020s[C]. New Orleans, LA, USA: 2022 IEEE/CVF Conference on Computer Vision and Pattern Recognition (CVPR), 2022: 11966-11976.
|
| 13 |
Vaswani A, Shazeer N, Parmar N, et al. Attention is all you need[J]. Adv Neural Inf Process Syst, 2017, 30: 5998-6008.
|
| 14 |
Russakovsky O, Deng J, Su H, et al. ImageNet large scale visual recognition challenge[J]. Int J Comput Vis, 2015, 115(3): 211-252.
|
| 15 |
De Rosa L, Ricco G, Brunetto MR, et al. Sustainability of general population screening for steatotic liver disease: a proof-of-concept study[J].Healthcare (Basel), 2025, 13(7): 759.
|
| 16 |
内分泌代谢科肥胖诊疗联盟,中国医师协会内分泌代谢科医师分会肥胖学组. 体重管理门诊建设专家指导意见(2025版)[J]. 中华糖尿病杂志, 2025, 17(7): 801-805.
|
| 17 |
Mihăilescu DM, Gui V, Toma CI, et al. Computer aided diagnosis method for steatosis rating in ultrasound images using random forests[J]. Med Ultrason, 2013, 15(3): 184-190.
|
| 18 |
Dinani AM, Kowdley KV, Noureddin M. Application of artificial intelligence for diagnosis and risk stratification in NAFLD and NASH: the state of the art[J]. Hepatology, 2021, 74(4): 2233-2240.
|
| 19 |
Zamanian H, Shalbaf A, Zali MR, et al. Application of artificial intelligence techniques for non-alcoholic fatty liver disease diagnosis: A systematic review (2005-2023)[J]. Comput Methods Programs Biomed, 2024, 244: 107932.
|
| 20 |
Vianna P, Calce SI, Boustros P, et al. Comparison of radiologists and deep learning for US grading of hepatic steatosis[J].Radiology, 2023, 309(1): e230659.
|
| 21 |
Tahmasebi A, Wang S, Wessner CE, et al. Ultrasound-based machine learning approach for detection of nonalcoholic fatty liver disease[J]. J Ultrasound Med, 2023, 42(8): 1747-1756.
|
| 22 |
Nan S, Liang Y, Qu Y, et al. Hepatic steatosis in chronic hepatitis B as measured by controlled attenuation parameter: frequency and distribution[J]. J Coll Physicians Surg Pak, 2019, 29(10): 937-941.
|
| 23 |
Bende R, Heredea D, Rațiu I, et al. Association between visceral adiposity and the prediction of hepatic steatosis and fibrosis in patients with metabolic dysfunction-associated steatotic liver disease (MASLD)[J]. J Clin Med, 2025, 14(10): 3405.
|